It is my belief that the science of 2-73 (and 3-71) is way beyond where the market is at present in understanding the future value and potential of this company.
An excellent point.
As I have expertise in business and investing but still consider myself (after years of study) a biotechnology layman, I am usually reluctant to mention 3-71 because it performs so ridiculously well in pre-clinical studies.
I will say, however, that there is no doubt that I am invested heavily in Anavex because of their short term pipeline (2-73) and their long term pipeline (3-71)
Too bad Anavex didn't attend the AES this year... if they had, I would have shown you the best bar in D.C... which is of course, the English pub
Cheers
Mycroft
"The hardest thing to explain is the glaringly evident which everybody has decided not to see.” - Ayn Rand.
